{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:09:35Z","timestamp":1788480575522,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T00:00:00Z","timestamp":1616284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T00:00:00Z","timestamp":1616284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Catania"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (\u2212\u00a049.61%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, <jats:italic>p<\/jats:italic> value for both\u2009&lt;\u20090.05) and PWV significantly decreased after PCSK9-i therapy (\u2212\u00a020.4%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Finally, simple regression analyses showed that \u2206 PWV was significantly associated with \u2206 LDL-C (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), \u2206 NC and \u2206 MHR (<jats:italic>p<\/jats:italic> value for both\u2009&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In conclusion, PCSK9-i therapy significantly improved lipid and inflammatory profiles and PWV values in FH subjects; our results support the positive effect of PCSK9-i in clinical practice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00592-021-01703-z","type":"journal-article","created":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T16:02:36Z","timestamp":1616342556000},"page":"949-957","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting"],"prefix":"10.1007","volume":"58","author":[{"given":"Roberto","family":"Scicali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Di Pino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata Maria","family":"Rabuazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7023-3649","authenticated-orcid":false,"given":"Francesco","family":"Purrello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Piro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,21]]},"reference":[{"key":"1703_CR1","doi-asserted-by":"publisher","first-page":"C7","DOI":"10.1016\/j.jacc.2005.09.068","volume":"47","author":"E Falk","year":"2006","unstructured":"Falk E (2006) Pathogenesis of Atherosclerosis. J Am Coll Cardiol 47:C7\u2013C12","journal-title":"J Am Coll Cardiol"},{"key":"1703_CR2","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I et al (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 38:2459\u20132472. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144","journal-title":"Eur Heart J"},{"key":"1703_CR3","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/nejmoa1912388","volume":"381","author":"J-C Tardif","year":"2019","unstructured":"Tardif J-C, Kouz S, Waters DD et al (2019) Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 381:2497\u20132505. https:\/\/doi.org\/10.1056\/nejmoa1912388","journal-title":"N Engl J Med"},{"key":"1703_CR4","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1093\/eurheartj\/ehaa160","volume":"41","author":"PM Ridker","year":"2020","unstructured":"Ridker PM, MacFadyen JG, Glynn RJ et al (2020) Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the cardiovascular inflammation reduction trial. Eur Heart J 41:2952\u20132961. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa160","journal-title":"Eur Heart J"},{"key":"1703_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21124459","volume":"21","author":"A Baragetti","year":"2020","unstructured":"Baragetti A, Catapano AL, Magni P (2020) Multifactorial activation of nlrp3 inflammasome: Relevance for a precision approach to atherosclerotic cardiovascular risk and disease. Int J Mol Sci 21:1\u201313","journal-title":"Int J Mol Sci"},{"key":"1703_CR6","first-page":"19","volume-title":"The complex interplay between lipids, immune system and interleukins in cardio-metabolic diseases","author":"S Bernardi","year":"2018","unstructured":"Bernardi S, Marcuzzi A, Piscianz E et al (2018) The complex interplay between lipids, immune system and interleukins in cardio-metabolic diseases. Int. J. Mol, Sci, p 19"},{"key":"1703_CR7","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.atherosclerosis.2008.09.025","volume":"204","author":"M Charakida","year":"2009","unstructured":"Charakida M, Tousoulis D, Skoumas I et al (2009) Inflammatory and thrombotic processes are associated with vascular dysfunction in children with familial hypercholesterolemia. Atherosclerosis 204:532\u2013537. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2008.09.025","journal-title":"Atherosclerosis"},{"key":"1703_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.010","author":"G Burden","year":"2020","unstructured":"Burden G, Roth GA, Mensah GA et al (2020) Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the gbd 2019 study. J Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.010","journal-title":"J Am Coll Cardiol"},{"key":"1703_CR9","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2014.03.003","volume":"234","author":"X Wang","year":"2014","unstructured":"Wang X, Zhang G, Jiang X et al (2014) Neutrophil to lymphocyte ratio in relation to risk of all-cause mortality and cardiovascular events among patients undergoing angiography or cardiac revascularization: A meta-analysis of observational studies. Atherosclerosis 234:206\u2013213","journal-title":"Atherosclerosis"},{"key":"1703_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/lipd.12276","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Wang L, Jia L et al (2020) The monocyte to high-density lipoprotein cholesterol ratio in the prediction for atherosclerosis: a retrospective study in adult chinese participants. Lipids. https:\/\/doi.org\/10.1002\/lipd.12276","journal-title":"Lipids"},{"key":"1703_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2017.07.001","author":"M Averna","year":"2017","unstructured":"Averna M, Cefal\u00f9 AB, Casula M et al (2017) Familial hypercholesterolemia: the Italian atherosclerosis society network (LIPIGEN). Atheroscler Suppl. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2017.07.001","journal-title":"Atheroscler Suppl"},{"key":"1703_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2017.07.002","author":"A Pirillo","year":"2017","unstructured":"Pirillo A, Garlaschelli K, Arca M et al (2017) Spectrum of mutations in Italian patients with familial hypercholesterolemia: new results from the LIPIGEN study. Atheroscler Suppl. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2017.07.002","journal-title":"Atheroscler Suppl"},{"key":"1703_CR13","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00592-019-01338-1","volume":"56","author":"R Scicali","year":"2019","unstructured":"Scicali R, Di Pino A, Urbano F et al (2019) Analysis of S100A12 plasma levels in hyperlipidemic subjects with or without familial hypercholesterolemia. Acta Diabetol 56:899\u2013906. https:\/\/doi.org\/10.1007\/s00592-019-01338-1","journal-title":"Acta Diabetol"},{"key":"1703_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.atherosclerosis.2018.08.013","volume":"277","author":"M Casula","year":"2018","unstructured":"Casula M, Olmastroni E, Pirillo A et al (2018) Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. Atherosclerosis 277:413\u2013418. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.08.013","journal-title":"Atherosclerosis"},{"key":"1703_CR15","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","volume":"141","author":"P Hu","year":"2020","unstructured":"Hu P, Dharmayat KI, Stevens CAT et al (2020) Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease. Circulation 141:1742\u20131759. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044795","journal-title":"Circulation"},{"key":"1703_CR16","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.3390\/ijms19113426","volume":"19","author":"A Benito-Vicente","year":"2018","unstructured":"Benito-Vicente A, Uribe KB, Jebari S et al (2018) Familial hypercholesterolemia: the most frequent cholesterol metabolism disorder caused disease. Int J Mol Sci 19:3426","journal-title":"Int J Mol Sci"},{"key":"1703_CR17","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jacl.2016.07.004","volume":"10","author":"DL Dixon","year":"2016","unstructured":"Dixon DL, Trankle C, Buckley L et al (2016) A review of PCSK9 inhibition and its effects beyond LDL receptors. J Clin Lipidol 10:1073\u20131080","journal-title":"J Clin Lipidol"},{"key":"1703_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-017-1089-4","author":"R Scicali","year":"2018","unstructured":"Scicali R, Di Pino A, Ferrara V et al (2018) New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. Acta Diabetol. https:\/\/doi.org\/10.1007\/s00592-017-1089-4","journal-title":"Acta Diabetol"},{"key":"1703_CR19","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M et al (2018) Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 379:2097\u20132107. https:\/\/doi.org\/10.1056\/NEJMoa1801174","journal-title":"N Engl J Med"},{"key":"1703_CR20","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC et al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713\u20131722. https:\/\/doi.org\/10.1056\/NEJMoa1615664","journal-title":"N Engl J Med"},{"key":"1703_CR21","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jacl.2017.02.014","volume":"11","author":"AMH Galema-Boers","year":"2017","unstructured":"Galema-Boers AMH, Lenzen MJ, Sijbrands EJ, Roeters van Lennep JE (2017) Proprotein convertase subtilisin\/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience. J Clin Lipidol 11:674\u2013681. https:\/\/doi.org\/10.1016\/j.jacl.2017.02.014","journal-title":"J Clin Lipidol"},{"key":"1703_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2017.07.003","author":"R Scicali","year":"2018","unstructured":"Scicali R, Di Pino A, Platania R et al (2018) Detecting familial hypercholesterolemia by serum lipid profile screening in a hospital setting: clinical, genetic and atherosclerotic burden profile. Nutr Metab Cardiovasc Dis. https:\/\/doi.org\/10.1016\/j.numecd.2017.07.003","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1703_CR23","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00592-018-1144-9","volume":"55","author":"R Scicali","year":"2018","unstructured":"Scicali R, Rosenbaum D, Di Pino A et al (2018) An increased waist-to-hip ratio is a key determinant of atherosclerotic burden in overweight subjects. Acta Diabetol 55:741\u2013749. https:\/\/doi.org\/10.1007\/s00592-018-1144-9","journal-title":"Acta Diabetol"},{"key":"1703_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2020.11.009","author":"R Scicali","year":"2020","unstructured":"Scicali R, Di Pino A, Urbano F et al (2020) Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: a single lipid center real-world experience. Nutr Metab Cardiovasc Dis. https:\/\/doi.org\/10.1016\/j.numecd.2020.11.009","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1703_CR25","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1530\/EJE-19-0173","volume":"181","author":"F Urbano","year":"2019","unstructured":"Urbano F, Di Pino A, Scicali R et al (2019) Impaired glucagon suppression and reduced insulin sensitivity in subjects with prediabetes undergoing atorvastatin therapy. Eur J Endocrinol 181:579\u2013590. https:\/\/doi.org\/10.1530\/EJE-19-0173","journal-title":"Eur J Endocrinol"},{"key":"1703_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.11.003","author":"R Scicali","year":"2016","unstructured":"Scicali R, Giral P, Gallo A et al (2016) HbA1c increase is associated with higher coronary and peripheral atherosclerotic burden in non diabetic patients. Atherosclerosis. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.11.003","journal-title":"Atherosclerosis"},{"key":"1703_CR27","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G et al (2016) 2016 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 37:2999\u20133058. https:\/\/doi.org\/10.1093\/eurheartj\/ehw272","journal-title":"Eur Heart J"},{"key":"1703_CR28","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.3390\/jcm9113597","volume":"9","author":"R Scicali","year":"2020","unstructured":"Scicali R, Russo GI, Di Mauro M et al (2020) Analysis of arterial stiffness and sexual function after adding on pcsk9 inhibitor treatment in male patients with familial hypercholesterolemia: a single lipid center real-world experience. J Clin Med 9:3597. https:\/\/doi.org\/10.3390\/jcm9113597","journal-title":"J Clin Med"},{"key":"1703_CR29","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jacl.2020.04.010","volume":"14","author":"G Mandraffino","year":"2020","unstructured":"Mandraffino G, Scicali R, Squadrito G (2020) Author\u2019s reply to: Arterial stiffness improvement after adding on PCSK9 inhibitors in patients with familial hypercholesterolemia, a letter from Papaioannou and colleagues. J Clin Lipidol 14:543","journal-title":"J Clin Lipidol"},{"key":"1703_CR30","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2014.985707","author":"L Spadaro","year":"2014","unstructured":"Spadaro L, Noto D, Privitera G et al (2014) Apolipoprotein AI and HDL are reduced in stable cirrhotic patients with adrenal insufficiency: a possible role in glucocorticoid deficiency. Scand J Gastroenterol. https:\/\/doi.org\/10.3109\/00365521.2014.985707","journal-title":"Scand J Gastroenterol"},{"key":"1703_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56857-2","author":"R Scicali","year":"2019","unstructured":"Scicali R, Di Pino A, Pavanello C et al (2019) Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-019-56857-2","journal-title":"Sci Rep"},{"key":"1703_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3367","author":"R Scicali","year":"2020","unstructured":"Scicali R, Giral P, D\u2019Erasmo L et al (2020) High TG to HDL ratio plays a significant role on atherosclerosis extension in prediabetes and newly diagnosed type 2 diabetes subjects. Diabetes Metab Res Rev. https:\/\/doi.org\/10.1002\/dmrr.3367","journal-title":"Diabetes Metab Res Rev"},{"key":"1703_CR33","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3390\/cells8080910","volume":"8","author":"A Di Pino","year":"2019","unstructured":"Di Pino A, Urbano F, Scicali R et al (2019) 1 h Postload Glycemia Is associated with low endogenous secretory receptor for advanced glycation end product levels and early markers of cardiovascular disease. Cells 8:910. https:\/\/doi.org\/10.3390\/cells8080910","journal-title":"Cells"},{"key":"1703_CR34","doi-asserted-by":"publisher","DOI":"10.1161\/atvbaha.120.314216","author":"D Flores-Gomez","year":"2020","unstructured":"Flores-Gomez D, Bekkering S, Netea MG, Riksen NP (2020) Trained Immunity in atherosclerotic cardiovascular disease. Arterioscler Thromb Vasc Biol. https:\/\/doi.org\/10.1161\/atvbaha.120.314216","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1703_CR35","doi-asserted-by":"publisher","DOI":"10.1161\/atvbaha.120.314215","author":"I Mitroulis","year":"2020","unstructured":"Mitroulis I, Hajishengallis G, Chavakis T (2020) Trained immunity and cardiometabolic disease. Arterioscler Thromb Vasc Biol. https:\/\/doi.org\/10.1161\/atvbaha.120.314215","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1703_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-017-0470-1","author":"T Rahman","year":"2017","unstructured":"Rahman T, Hamzan NS, Mokhsin A et al (2017) Enhanced status of inflammation and endothelial activation in subjects with familial hypercholesterolaemia and their related unaffected family members: a case control study. Lipids Health Dis. https:\/\/doi.org\/10.1186\/s12944-017-0470-1","journal-title":"Lipids Health Dis"},{"key":"1703_CR37","doi-asserted-by":"publisher","first-page":"462","DOI":"10.5551\/jat.RV17003","volume":"24","author":"MD Shapiro","year":"2017","unstructured":"Shapiro MD, Fazio S (2017) PCSK9 and atherosclerosis - lipids and beyond. J Atheroscler Thromb 24:462\u2013472","journal-title":"J Atheroscler Thromb"},{"key":"1703_CR38","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/cvr\/cvv178","volume":"107","author":"Z Ding","year":"2015","unstructured":"Ding Z, Liu S, Wang X et al (2015) Cross-Talk between LOX-1 and PCSK9 in vascular tissues. Cardiovasc Res 107:556\u2013567. https:\/\/doi.org\/10.1093\/cvr\/cvv178","journal-title":"Cardiovasc Res"},{"key":"1703_CR39","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.atherosclerosis.2014.04.001","volume":"234","author":"S Li","year":"2014","unstructured":"Li S, Guo YL, Xu RX et al (2014) Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis 234:441\u2013445. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.04.001","journal-title":"Atherosclerosis"},{"key":"1703_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20425-x","author":"C Ricci","year":"2018","unstructured":"Ricci C, Ruscica M, Camera M et al (2018) PCSK9 induces a pro-inflammatory response in macrophages. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-018-20425-x","journal-title":"Sci Rep"},{"key":"1703_CR41","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1111\/bcp.12905","volume":"81","author":"A Sahebkar","year":"2016","unstructured":"Sahebkar A, Di Giosia P, Stamerra CA et al (2016) Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: A meta-analysis of 16 randomized controlled treatment arms. Br J Clin Pharmacol 81:1175\u20131190. https:\/\/doi.org\/10.1111\/bcp.12905","journal-title":"Br J Clin Pharmacol"},{"key":"1703_CR42","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1194\/jlr.M051326","volume":"55","author":"S K\u00fchnast","year":"2014","unstructured":"K\u00fchnast S, Van Der Hoorn JWA, Pieterman EJ et al (2014) Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res 55:2103\u20132112. https:\/\/doi.org\/10.1194\/jlr.M051326","journal-title":"J Lipid Res"},{"key":"1703_CR43","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 376:1670\u20131681. https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5","journal-title":"Lancet"},{"key":"1703_CR44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/jama.286.1.64","volume":"286","author":"MA Albert","year":"2001","unstructured":"Albert MA, Danielson E, Rifai N, Ridker PM (2001) Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation\/CRP evaluation (PRINCE): a randomized trial and cohort study. J Am Med Assoc 286:64\u201370. https:\/\/doi.org\/10.1001\/jama.286.1.64","journal-title":"J Am Med Assoc"},{"key":"1703_CR45","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/10641963.2017.1411498","volume":"40","author":"D\u2019elia L, La Fata E, Iannuzzi A, Ru","year":"2018","unstructured":"D\u2019elia L, La Fata E, Iannuzzi A, Rubba PO, (2018) Effect of statin therapy on pulse wave velocity: a meta-analysis of randomized controlled trials. Clin Exp Hypertens 40:601\u2013608. https:\/\/doi.org\/10.1080\/10641963.2017.1411498","journal-title":"Clin Exp Hypertens"},{"key":"1703_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13219","author":"M Casula","year":"2020","unstructured":"Casula M, Gazzotti M, Bonaiti F et al (2020) Reported muscle symptoms during statin treatment among Italian dyslipidemic patients in the real-life setting: the prosisa study. J Intern Med. https:\/\/doi.org\/10.1111\/joim.13219","journal-title":"J Intern Med"},{"key":"1703_CR47","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2020.07.007","volume":"308","author":"MM Gulizia","year":"2020","unstructured":"Gulizia MM, Maggioni AP, Abrignani MG et al (2020) Prevalence of familial hypercholeSTerolaemia (FH) in Italian patients with coronary artERy disease: The poster study. Atherosclerosis 308:32\u201338. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.07.007","journal-title":"Atherosclerosis"},{"key":"1703_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-020-00411-3","author":"T Hollstein","year":"2020","unstructured":"Hollstein T, Kassner U, Grenkowitz T et al (2020) PCSK9 inhibitors in a German single-center clinical practice: real-world treatment of patients at high cardiovascular risk Over 68 weeks. Am J Cardiovasc Drugs. https:\/\/doi.org\/10.1007\/s40256-020-00411-3","journal-title":"Am J Cardiovasc Drugs"},{"key":"1703_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2020.01.015","author":"G Mandraffino","year":"2020","unstructured":"Mandraffino G, Scicali R, Rodr\u00edguez-Carrio J et al (2020) Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: a two-lipid center real-world experience. J Clin Lipidol. https:\/\/doi.org\/10.1016\/j.jacl.2020.01.015","journal-title":"J Clin Lipidol"},{"key":"1703_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2019.01.010","volume-title":"Improvement in arterial stiffness after short-term treatment with PCSK9 inhibitors","author":"AFG Cicero","year":"2019","unstructured":"Cicero AFG, Toth PP, Fogacci F et al (2019) Improvement in arterial stiffness after short-term treatment with PCSK9 inhibitors. Nutr. Metab. Cardiovasc, Dis"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-021-01703-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-021-01703-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-021-01703-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T04:05:12Z","timestamp":1623125112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-021-01703-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,21]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1703"],"URL":"https:\/\/doi.org\/10.1007\/s00592-021-01703-z","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"value":"0940-5429","type":"print"},{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,21]]},"assertion":[{"value":"3 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the local ethics committee in accordance with the ethical standards of the institutional and national research committees and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.Informed consent.Informed consent was obtained from each participant enrolled in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}